Guidance for reporting a prediction model development/validation

This advice is relevant to studies reporting prediction models (both diagnostic and prognostic) and is based on the TRIPOD statement.  Read more

The following information was originally published here.

Go to checklist

Title

1.

Identify the study as developing and / or validating a multivariable prediction model, the target population, and the outcome to be predicted.

Abstract

2.

Provide a summary of objectives, study design, setting, participants, sample size, predictors, outcome, statistical analysis, results, and conclusions.

Introduction

3a

Explain the medical context (including whether diagnostic or prognostic) and rationale for developing or validating the multivariable prediction model, including references to existing models.

3b

Specify the objectives, including whether the study describes the development or validation of the model or both.

Methods

4a Source of data

Describe the study design or source of data (e.g., randomized trial, cohort, or registry data), separately for the development and validation data sets, if applicable.

4b Source of data

Specify the key study dates, including start of accrual; end of accrual; and, if applicable, end of follow-up.

5a Participants

Specify key elements of the study setting (e.g., primary care, secondary care, general population) including number and location of centres.

5b Participants

Describe eligibility criteria for participants.

5c Participants

Give details of treatments received, if relevant.

6a Outcome

Clearly define the outcome that is predicted by the prediction model, including how and when assessed.

6b Outcome

Report any actions to blind assessment of the outcome to be predicted.

7a Predictors

Clearly define all predictors used in developing or validating the multivariable prediction model, including how and when they were measured.

7b Predictors

Report any actions to blind assessment of predictors for the outcome and other predictors.

8. Sample size

Explain how the study size was arrived at.

9. Missing data

Describe how missing data were handled (e.g., complete-case analysis, single imputation, multiple imputation) with details of any imputation method.

10a Statistical analysis methods

If you are developing a prediction model describe how predictors were handled in the analyses.

10b Statistical analysis methods

If you are developing a prediction model, specify type of model, all model-building procedures (including any predictor selection), and method for internal validation.

10c Statistical analysis methods

If you are validating a prediction model, describe how the predictions were calculated.

10d Statistical analysis methods

Specify all measures used to assess model performance and, if relevant, to compare multiple models.

10e Statistical analysis methods

If you are validating a prediction model, describe any model updating (e.g., recalibration) arising from the validation, if done.

11. Risk groups

Provide details on how risk groups were created, if done.

12. Development vs. validation

For validation, identify any differences from the development data in setting, eligibility criteria, outcome, and predictors.

Results

13a Participants

Describe the flow of participants through the study, including the number of participants with and without the outcome and, if applicable, a summary of the follow-up time. A diagram may be helpful.

13b Participants

Describe the characteristics of the participants (basic demographics, clinical features, available predictors), including the number of participants with missing data for predictors and outcome.

13c Participants

For validation, show a comparison with the development data of the distribution of important variables (demographics, predictors and outcome).

14a Model development

If developing a model, specify the number of participants and outcome events in each analysis.

14b Model development

If developing a model, report the unadjusted association, if calculated between each candidate predictor and outcome.

15a Model specification

If developing a model, present the full prediction model to allow predictions for individuals (i.e., all regression coefficients, and model intercept or baseline survival at a given time point).

15b Model specification

If developing a prediction model, explain how to the use it.

16. Model performance

Report performance measures (with CIs) for the prediction model.

17. Model-updating

If validating a model, report the results from any model updating, if done (i.e., model specification, model performance).

Discussion

18. Limitations

Discuss any limitations of the study (such as nonrepresentative sample, few events per predictor, missing data).

19a Interpretation

For validation, discuss the results with reference to performance in the development data, and any other validation data.

19b Interpretation

Give an overall interpretation of the results, considering objectives, limitations, results from similar studies, and other relevant evidence.

20. Implications

Discuss the potential clinical use of the model and implications for future research.

Other information

21. Supplementary information

Provide information about the availability of supplementary resources, such as study protocol, Web calculator, and data sets.

22. Funding

Give the source of funding and the role of the funders for the present study.

To acknowledge this checklist in your methods, please state "We used the TRIPOD checklist when writing our report [citation]". Then cite this checklist as Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): The TRIPOD statement..

The TRIPOD checklist is distributed under the terms of the Creative Commons Attribution License CC-BY